A failed drug trial in non-small lung Ca & another one with pre-treatment & combo therapy trial. The comment of Novel treatment beyond targeting T-cells was interesting:
“The study, called EMERGE, was testing three dose levels of Jounce’s drug, vopratelimab, with Opdivo in 59 patients who had already tried PD-1 or PD-L1 inhibitors like Bristol Myers Squibb’s Opdivo or Merck’s Keytruda. Yervoy works by targeting CTLA-4, a receptor found on T cells that acts as a “brake” on the immune system. Adding vopratelimab to the mix, Jounce thought, would activate ICOS, a different protein on the T cells, to boost their proliferation and expansion after Yervoy released the immune brake. But data from 50 evaluable patients said otherwise.”
https://www.fiercebiotech.com/biotech/jounce-sinks-as-it-ditches-phase-2-yervoy-combo-trial“The PD-(L)1 experienced or resistant population continues to prove difficult to treat. To bring necessary benefit to these patients it is becoming clearer that novel approaches beyond T cells may be needed as part of the solution,” Jounce CEO Richard Murray, Ph.D., said in the statement.
- Forums
- ASX - By Stock
- IMU
- Media Thread
Media Thread, page-60
-
-
- There are more pages in this discussion • 14,490 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $387.9M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 34222 | 5.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 8040 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 33960 | 0.058 |
1 | 450000 | 0.054 |
2 | 200358 | 0.053 |
1 | 96153 | 0.052 |
8 | 971078 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 8040 | 2 |
0.051 | 500000 | 1 |
0.052 | 141000 | 3 |
0.053 | 1236540 | 6 |
0.054 | 1341488 | 7 |
Last trade - 09.59am 05/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
Day chart unavailable